SYBLEU, Inc. (OTC PINK: SYBE) is a biotechnology company committed to advancing healthcare for humans and animals. Our dedication lies in the development and commercialization of therapies, medical devices, and clinical diagnostics. We actively pursue strategic acquisitions and in-licensing opportunities to expand our intellectual property portfolio and seek strategic partnerships to bring these technologies to market.
SYBLEU, Inc. (OTC PINK: SYBE) is a leading biotechnology company committed to advancing healthcare for humans and animals. Our dedication lies in the development and promotion of therapies, medical devices, and clinical diagnostics. To expand our intellectual property portfolio, we actively seek strategic acquisitions and in-licensing prospects. Moreover, we facilitate financing and establish strategic partnerships to ensure the successful market introduction of these innovative technologies. At SYBLEU, we assemble proficient senior management teams to achieve our objectives.
Putting together the brightest minds involved in drug development, medical device innovation and cutting edge diagnostics to promote animal and human health as rapidly as possible.
Putting together the brightest minds involved in drug development, medical device innovation and cutting edge diagnostics to promote animal and human health as rapidly as possible.
Patent / Application Number | Title | Patent Type |
---|---|---|
US 2022/0168240 A1 | CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC AGENT IN COMBINATI... | Pending |
US 2022/0031912 A1 | Quality of a cellular graft | Pending |
Patent / Application Number | Title | Patent Type |
---|---|---|
US 2022/0168240 A1 | CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC AGENT IN COMBINATI... | Pending |
US 2022/0031912 A1 | Quality of a cellular graft | Pending |